Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Reduction in MPN-Total Symptom Score (TSS) Is Associated with Overall Survival (OS) in Chronic Myelomonocytic Leukemia (CMML)

Eric Padron, Wenyi Fan, Sara M. Tinsley-Vance, Amy E. DeZern, Hetty E. Carraway, Marlise R. Luskin, Gail J. Roboz, Onyee Chan, Aaron T. Gerds, Andrew T. Kuykendall, David P. Steensma, Maria Balasis, Jeffrey E Lancet, Qianxing Mo, Mikkael A. Sekeres, David Sallman, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 6750.

https://doi.org/10.1182/blood-2024-211137

Published: 2024

Journal Articles

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Andrew T. Kuykendall, Tania Jain, Abhay Singh, Kristen M. Pettit, Quan Lovette, Joan McFadden Cain, Tracy Ann Cinalli, Mary Gallagher, David Sallman, Qianxing Mo, Ling Zhang, Onyee Chan, Alison R. Walker, Zhuoer Xie, Jeffrey E Lancet, Maria Balasis, Seongseok Yun, Eric Padron, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 481.

https://doi.org/10.1182/blood-2024-210743

Published: 2024

Journal Articles

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Andrew T. Kuykendall, Kristen Marie Pettit, Abhay Singh, Tania Jain, David A Sallman, Qianxing Mo, Quan Lovette, Ling Zhang, Onyee Chan, Alison R. Walker, Zhuoer Xie, Jeffrey Lancet, Maria Balasis, Seongseok Yun, Eric Padron, Rami S. Komrokji

Blood (2023) 142 (Supplement 1): 73.

https://doi.org/10.1182/blood-2023-182879

Published: 2023

Journal Articles

Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation

Blood (2022) 139 (7): 1066–1079.

https://doi.org/10.1182/blood.2021012519

Published: 2022

Includes: Supplemental data

Journal Articles

Single Cell Deconvolution of Myeloblasts Reveals Depletion of HSCs and Expansion of Inflammatory Granulocyte-Monocyte Progenitors (GMPs) Associated with Adverse Outcomes in Chronic Myelomonocytic Leukemia (CMML)

Abhishek Dhawan, Meghan Ferrall-Fairbanks, Brian Johnson, Hannah Newman, Virginia Volpe, Christopher Letson, Anthony M. Hunter, Maria Balasis, Traci L. Kruer, Jodi Kroeger, Robert Balderas, Rami S. Komrokji, David A. Sallman, Rafael Bejar, Philipp M. Altrock, Eric Padron

Blood (2021) 138 (Supplement 1): 319.

https://doi.org/10.1182/blood-2021-151348

Published: 2021

Journal Articles

Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

Eric Padron, MD, Amy E. DeZern, MD, Sandrine Niyongere, MD, Markus Christian Ball, PhD, Maria Balasis, Hanadi Ramadan, BA, Jeffrey E. Lancet, MD, Alan F List, MD, Ruben A Mesa, MD, Gail J. Roboz, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS, Rami S. Komrokji, MD

Blood (2017) 130 (Supplement 1): 162.

https://doi.org/10.1182/blood.V130.Suppl_1.162.162

Published: 2017

Journal Articles

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl–expressing human leukemia cells

Warren Fiskus, Michael Pranpat, Purva Bali, Maria Balasis, Sandhya Kumaraswamy, Sandhya Boyapalle, Kathy Rocha, Jie Wu, Francis Giles, Paul W. Manley, Peter Atadja, Kapil Bhalla

Blood (2006) 108 (2): 645–652.

https://doi.org/10.1182/blood-2005-11-4639

Published: 2006

Journal Articles

Histone Deacetylase Inhibitors LBH589 and LAQ824 Deplete Ezh2 and Associated Polycomb Repressive Complex 2/3 Proteins Resulting in Downregulation of HOXA9 and MEIS1 Expression in Human Acute Leukemia Cells.

Warren Fiskus, PhD, Michael Pranpat, MS, Purva Bali, MS, Sandhya Kumaraswamy, PhD, Sandhya Boyapalle, PhD, Kathy Rocha, BS, Maria Balasis, BS, Peter Atadja, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 2482.

https://doi.org/10.1182/blood.V106.11.2482.2482

Published: 2005

Journal Articles

Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells.

Angela Hatter, BS, Purva Bali, MS, Maria Balasis, BS, Warren Fiskus, PhD, Sandhya Boyapalle, PhD, Sandhya Kumaraswamy, PhD, Kathy Rocha, BS, Michael Pranpat, BS, Alison Hannah, MD, Eduardo Sotomayor, MD, PhD, Victoria Richon, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 2418.

https://doi.org/10.1182/blood.V106.11.2418.2418

Published: 2005

Journal Articles

Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells.

Sandhya Kumaraswamy, PhD, Que T. Lambert, MS, Kathy Rocha, BS, Purva Bali, MS, Warren Fiskus, PhD, Maria Balasis, BS, Michael Pranpat, MS, Sandhya Boyapalle, PhD, Alison Hannah, MD, Gary W. Reuther, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 4401.

https://doi.org/10.1182/blood.V106.11.4401.4401

Published: 2005

Journal Articles

Co-Treatment with a Novel Heat Shock Protein (hsp) 90 Inhibitor IPI504 and the Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Wild Type or Mutant Bcr-Abl-T315I or FLT-3-ITD-Containing Human Leukemia Cells.

Warren Fiskus, PhD, Purva Bali, MS, Michael Pranpat, MS, Maria Balasis, BS, Sandhya Kumaraswamy, PhD, Sandhya Boyapalle, PhD, Kathy Rocha, BS, Jeffery Tong, MD, Victoria Richon, PhD, Emmanuel Normant, PhD, Kapil Bhalla, MD

Blood (2005) 106 (11): 4461.

https://doi.org/10.1182/blood.V106.11.4461.4461

Published: 2005

Journal Articles

Increased Levels of the Heat Shock Protein (hsp) 70 Contribute as a Pro-Survival and Pro-Growth Mechanism in the Transformation of Bone Marrow Progenitor Cells.

Sandhya Boyapalle, PhD, Kathy Rocha, BS, Fei Guo, PhD, Purva Bali, MS, Maria Balasis, BS, Warren Fiskus, PhD, Sandhya Kumaraswamy, PhD, Michael Pranpat, MS, Kapil Bhalla, MD

Blood (2005) 106 (11): 1374.

https://doi.org/10.1182/blood.V106.11.1374.1374

Published: 2005

NARROW

Reduction in MPN-Total Symptom Score (TSS) Is Associated with Overall Survival (OS) in Chronic Myelomonocytic Leukemia (CMML)

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation

Single Cell Deconvolution of Myeloblasts Reveals Depletion of HSCs and Expansion of Inflammatory Granulocyte-Monocyte Progenitors (GMPs) Associated with Adverse Outcomes in Chronic Myelomonocytic Leukemia (CMML)

Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl–expressing human leukemia cells

Histone Deacetylase Inhibitors LBH589 and LAQ824 Deplete Ezh2 and Associated Polycomb Repressive Complex 2/3 Proteins Resulting in Downregulation of HOXA9 and MEIS1 Expression in Human Acute Leukemia Cells.

Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells.

Treatment with the Heat Shock Protein (hsp) 90 Inhibitor17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) Abrogates the Levels and Activity of the Receptor Tyrosine Kinase TrkA in Acute Leukemia Cells.

Co-Treatment with a Novel Heat Shock Protein (hsp) 90 Inhibitor IPI504 and the Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Wild Type or Mutant Bcr-Abl-T315I or FLT-3-ITD-Containing Human Leukemia Cells.

Increased Levels of the Heat Shock Protein (hsp) 70 Contribute as a Pro-Survival and Pro-Growth Mechanism in the Transformation of Bone Marrow Progenitor Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only